Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer: early-phase trial registry
101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count
Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.
Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer
OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer recruits in line with its size-band peers.
101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.
-
Pancreatic Cancer research is mostly interventional.
237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 2 of 6
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03190941
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Medical College of Wisconsin
NCT03704662
Pancreatic Cancer Genetics
Columbia University
NCT01102569
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05227326
A Study of Multiparametric Ultrasound Imaging Methods
Memorial Sloan Kettering Cancer Center
NCT07270237
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
Medical College of Wisconsin
NCT04683315
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
CivaTech Oncology
NCT02843945
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
H. Lee Moffitt Cancer Center and Research Institute
NCT06001268
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Prestige Biopharma Limited
NCT05141149
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell
NCT02584244
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
NCT02598349
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
M.D. Anderson Cancer Center
NCT05053555
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Washington University School of Medicine
NCT05975593
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
Ohio State University
NCT04588025
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06411691
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
NCT05922930
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT06648434
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
THERABIONIC
NCT05776524
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
Wake Forest University Health Sciences
NCT06291324
Lidocaine Infusion in Pancreatic Cancer
University of Illinois at Chicago
NCT04048278
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
NCT03454035
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
Dana-Farber Cancer Institute
NCT05356117
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06782932
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05013216
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
NCT05394259
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Alpha Tau Medical
NCT06698458
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
NCT05837767
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
NCT06673017
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06423963
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
NCT05462496
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05141513
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
University of Virginia
NCT06479239
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
University of Kansas Medical Center
NCT06736717
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06941857
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
University of Rochester
NCT04477343
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Cedars-Sinai Medical Center
NCT05086250
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Diakonos Oncology Corporation
NCT04157127
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
NCT06205849
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NYU Langone Health
NCT05723107
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
NCT05497531
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
West Virginia University
NCT05535894
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
NCT05984602
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
Northwell Health
NCT07254091
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 114 |
| Phase 2 | 66 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer page
283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 101 Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.